anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Budesonide is secreted in human milk. Data with budesonide delivered via dry powder inhaler indicates that the total daily oral dose of budesonide available in breast milk to the infant is approximately 0.3% to 1% of the dose inhaled by the mother [see Clinical Pharmacology, Pharmacokinetics, Special Populations, Nursing (12.3)]. No studies have been conducted in breastfeeding women specifically with RHINOCORT AQUA Nasal Spray; however, the dose of budesonide available to the infant in breast milk, as a percentage of the maternal dose, would be expected to be similar. RHINOCORT AQUA Nasal Spray should be used in nursing women only if clinically appropriate. Prescribers should weigh the known benefits of breastfeeding for the mother and infant against the potential risks of minimal budesonide exposure in the infant. Dosing considerations include prescription or titration to the lowest clinically effective dose and use of RHINOCORT AQUA Nasal Spray immediately after breastfeeding to maximize the time interval between dosing and breastfeeding to minimize infant exposure.
Hyperalgesia occurs in the orofacial region of rats when estrogen levels are low, although the specific mechanism needs to be investigated further. Furthermore, oxidative stress plays an important role in the transmission of pain signals. This study aimed to explore the role of oxidative stress in orofacial hyperalgesia under low estrogen conditions. We firstly found an imbalance between oxidative and antioxidant capacity within the spinal trigeminal subnucleus caudalis (SP5C) of rats after ovariectomy (OVX), resulting in oxidative stress and then a decrease in the orofacial pain threshold. To investigate the mechanism by which oxidative stress occurs, we used virus as a tool to silence or overexpress the excitatory amino acid transporter 3 (EAAT3) gene. Further investigation revealed that the regulation of glutathione (GSH) and reactive oxygen species (ROS) can be achieved by regulating EAAT3, which in turn impacts the occurrence of oxidative stress. In summary, our findings suggest that reduced expression of EAAT3 within the SP5C of rats in the low estrogen state may decrease GSH content and increase ROS levels, resulting in oxidative stress and ultimately lead to orofacial hyperalgesia. This suggests that antioxidants could be a potential therapeutic direction for orofacial hyperalgesia under low estrogen conditions, though more research is needed to understand its mechanism.
Experimental group. The application of TENS has been added to the physiotherapy program. It had a frequency of 100 Hz and a phase duration of 100 µsec for a period of 30 minutes (through channel 1 of the TENS equipment), receiving and feeling the patient the physical sensation of the current.
Systems, methods, and software products analyze healthcare data. First input data is collected from a first source and second input data is collected from a second source disparate from the first source. The second source has a data format that is different from a format of the first source. The first input data is processed to determine a first concept and the second input data is processed to determine a second concept. A relationship between the first and second concepts is determined. The first and second concepts are stored within a knowledgebase based upon the relationship and a patient medical model is generated from the knowledgebase.
The efficacy and safety of zoledronic acid injection in postmenopausal women with osteopenia (low bone mass) was assessed in a 2-year randomized, multi-center, double-blind, placebo-controlled study of 581 postmenopausal women aged greater than or equal to 45 years, who were stratified by years since menopause: Stratum I women less than 5 years from menopause (n=224); Stratum II women greater than or equal to 5 years from menopause (n=357). Patients within Stratum I and II were randomized to one of three treatment groups: (1) Zoledronic acid injection given at randomization and at Month 12 (n=77) in Stratum I and (n=121) in Stratum II; (2) Zoledronic acid injection given at randomization and placebo at Month 12 (n=70) in Stratum I and (n=111) in Stratum II; and (3) Placebo given at randomization and Month 12 (n=202). Zoledronic acid injection was administered as a single 5 mg dose in 100 mL solution infused over at least 15 minutes. All women received 500 to 1200 mg elemental calcium plus 400 to 800 international units vitamin D supplementation per day. The primary efficacy variable was the percent change of BMD at 24 Months relative to baseline.

Effect on Bone Mineral Density (BMD)

Zoledronic acid injection significantly increased lumbar spine BMD relative to placebo at Month 24 across both strata. Zoledronic acid injection given once at randomization (and placebo given at Month 12) resulted in 4.0% increase in BMD in Stratum I patients and 4.8% increase in Stratum II patients over 24 months. Placebo given at randomization and at Month 12 resulted in 2.2% decrease in BMD in Stratum I patients and 0.7% decrease in BMD in Stratum II patients over 24 months. Therefore, zoledronic acid injection given once at randomization (and placebo given at Month 12) resulted in a 6.3% increase in BMD in Stratum I patients and 5.4% increase in Stratum II patients over 24 months as compared to placebo (both p<0.0001).

Zoledronic acid injection also significantly increased total hip BMD relative to placebo at Month 24 across both strata. Zoledronic acid injection given once at randomization (and placebo given at Month 12) resulted in 2.6% increase in BMD in Stratum I patients and 2.1% in Stratum II patients over 24 months. Placebo given at randomization and at Month 12 resulted in 2.1% decrease in BMD in Stratum I patients and 1.0% decrease in BMD in Stratum II patients over 24 months. Therefore, zoledronic acid injection given once at randomization (and placebo given at Month 12) resulted in a 4.7% increase in BMD in Stratum I patients and 3.2% increase in Stratum II patients over 24 months as compared to placebo (both p<0.0001).
<P>PROBLEM TO BE SOLVED: To obtain a coenzyme Q10 preparation that is efficiently and orally absorbed even in a person having poor oral absorption of coenzyme Q10, readily taken even in an aged person and a sick person and has improved oral absorption.  <P>SOLUTION: The coenzyme Q10 oral preparation having improved absorption is prepared by dispersing coenzyme Q10 into a saturated fatty acid polyhydric alcohol ester solid at a normal temperature. Preferably the blending ratio is 0.1-100 parts wt. of coenzyme Q10 based on 100 parts wt. of the saturated fatty acid polyhydric alcohol ester. An 8-22C saturated fatty acid glycerol ester is preferably used as the saturated fatty acid polyhydric alcohol ester.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
AIMS: Primary sclerosing cholangitis (PSC) is a cholestatic liver disease that affects the hepatic bile ducts, leading to hepatic inflammation and fibrosis. PSC can also impact skeletal muscle through the muscle-liver axis, resulting in sarcopenia, a complication characterized by a generalized loss of muscle mass and strength. The underlying mechanisms and therapy of PSC-induced sarcopenia are not well understood, but one potential regulator is the transcription factor forkhead box protein O1 (FOXO1), which is involved in the ubiquitin proteasome system. Thus, the aim of this study is to assess the pharmacological potential of FOXO1 inhibition for treating PSC-induced sarcopenia.
MATERIALS AND METHODS: To establish diet-induced PSC model, we provided mice with a 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet for 4 weeks. Mice were intramuscularly injected with AS1842856 (AS), a FOXO1 inhibitor, at a dose of 3.5 mg/kg twice a week for last two weeks. C2C12 myotubes with cholic acid (CA) or deoxycholic acid (DCA) were treated with AS.
KEY FINDINGS: We observed a decrease in muscle size and performance in DDC-fed mice with upregulated expression of FOXO1 and E3 ligases such as ATROGIN1 and MuRF1. We found that myotube diameter and MyHC protein level were decreased by CA or DCA in C2C12 myotubes, but treatment of AS reversed these reductions. We observed that intramuscular injection of AS effectively mitigates DDC diet-induced sarcopenia in a rodent PSC model.
SIGNIFICANCE: Our study suggests that a FOXO1 inhibitor could be a potential leading therapeutic drug for relieving PSC-induced sarcopenia.
OBJECTIVE: Evidence regarding the modifying effect of the polygenic risk score (PRS) on the associations between glycemic traits and hearing loss (HL) was lacking. We aimed to examine whether these associations can be influenced by genetic susceptibility.
RESEARCH DESIGN AND METHODS: This cross-sectional study included 13,275 participants aged 64.9 years from the Dongfeng-Tongji cohort. HL was defined according to a pure tone average >25 dB in the better ear and further classified by severity. Prediabetes and type 2 diabetes (T2D) were defined based on the 2013 criteria from the American Diabetes Association. A PRS was derived from 37 single nucleotide polymorphisms associated with HL. Multivariable logistic regression models were fitted to estimate the associations of PRS and glycemic traits with HL and its severity.
RESULTS: Elevated fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), and T2D were positively associated with higher HL risks and its severity, with odds ratios (ORs) ranging from 1.04 (95% CI 1.00, 1.08) to 1.25 (95% CI 1.06, 1.46). We also found significant interaction between HbA1c and PRS on risks of overall HL and its severity (P for multiplicative interaction <0.05), and the effects of HbA1c on HL risks were significant only in the group with high PRS. Additionally, compared with normoglycemia in the group with low PRS, T2D was associated with an OR of up to 2.00 and 2.40 for overall HL and moderate to severe HL, respectively, in the group with high PRS (P for additive interaction <0.05).
CONCLUSIONS: PRS modifies the association of HbA1c with HL prevalence among middle-aged and older Chinese individuals.
For JRA, the dosage for pediatric patients (age 2 years and older) is based on weight. For patients ≥10 kg to ≤25 kg the recommended dose is 50 mg twice daily. For patients >25 kg the recommended dose is 100 mg twice daily.   
  
For patients who have difficulty swallowing capsules, the contents of a celecoxib capsule can be added to applesauce. The entire capsule contents are carefully emptied onto a level teaspoon of cool or room temperature applesauce and ingested immediately with water. The sprinkled capsule contents on applesauce are stable for up to 6 hours under refrigerated conditions (2° C to 8° C/ 35° F to 45° F).
The summary description and intended purpose of the investigational device (LOQTEQ® antibacterial silver-coated system) is the same as that of the comparator device (LOQTEQ® 3.5 System (uncoated) system). The investigational device differs from the comparator device in that its surface which has been modified by the addition of an antibacterial coating.
Beginning on day 1, patients undergo intensity modulated re-irradiation therapy (IMRRT) 5 days a week (Monday-Friday). Participants also receive birinapant intravenous (IV) over 30 minutes on days 2 and 9 of each cycle. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Chronic rhinosinusitis (CRS) is a chronic inflammatory disease with an autoimmune background. Altered expression levels of T cell immunoglobulin and mucin-domain containing-3 (TIM-3), C-X-C chemokine receptor type 5 (CXCR5), and programmed cell death protein 1 (PD-1) are implicated in the progression of inflammatory and autoimmune diseases. Moreover, CXCR5+TIM-3-PD-1+ stem-like cytotoxic T cells function as memory stem cells during chronic disease processes and retain cytotoxicity-related gene networks.
OBJECTIVES: To explore the expressions of CXCR5, TIM-3, and PD-1 on T cells and their correlation with clinical parameters in CRS.
METHODS: Flow cytometry was used to assess the expressions and co-expressions of CXCR5, TIM-3, and PD-1 on T cells in the tissues of the paranasal sinus and peripheral blood of patients with CRS as well as healthy controls. Immunofluorescence was used to assess the co-localization of TIM-3, CXCR5, and PD-1 with T cells. The disease severity of our patients with CRS was evaluated using the Lund-Mackay score. A complete blood count was also performed for the patients with CRS.
RESULTS: Expression levels of CXCR5 and PD-1 on T cells were significantly increased in the nasal tissues of patients with CRS. Compared with those in healthy controls, patients with CRS had high percentages of CXCR5+TIM-3-PD-1+ CD8+ and CD4+ T cells in nasal tissues, while no significant difference was observed in peripheral blood levels. Patients with CRS had a higher density of nasal CXCR5+TIM-3-PD-1+ T cells than that in healthy controls. CXCR5+TIM-3-PD-1+ CD8+ T cell levels in the nasal polyps of patients with CRS were negatively correlated with the patients' Lund-Mackay scores. The levels of CXCR5+TIM-3-PD-1+ T cells in nasal tissues were also negatively associated with disease duration and positively associated with the chronic inflammatory state of CRS.
CONCLUSIONS: The level of CXCR5+TIM-3-PD-1+ stem cell-like T cells, especially CXCR5+TIM-3-PD-1+ CD8+ T cells, is increased in CRS. Therefore, inducing CXCR5+TIM-3-PD-1+ T cell exhaustion may be an effective immunotherapy for CRS.
Volunteers are randomly assigned to one of three groups: 1). 8 weeks of resistance (strength) training followed by 8 weeks of bicycle exercise training, 2). 8 weeks of chair exercise followed by 8 weeks of resistance (strength) training and bicycle exercise training, or 3). 8 weeks of chair exercise followed by 8 weeks of bicycle exercise training. The length of the training is 16 weeks for all 3 groups. Volunteers train 3 days per week in our lab located in the Chicagoland area and are supervised by an exercise specialist.
As a pre-test, pulse, respiratory rate, blood pressure and saturation values will be checked, Descriptive Questionnaire and General Comfort Scale (GAS) will be applied to the primiparous pregnant women in the experimental groups. Breathing therapy exercises based on Kolcaba's comfort theory were designed as face-to-face training by the researcher himself, who received breathing therapy training for primiparous pregnant women once a week, for a total of 8 sessions. 6 pieces will be created within the session. Each session lasts approximately 45-60 minutes. As the final test, pulse, respiratory rates, blood pressure and saturation values will be checked again at the end of the 8th session/week to determine the change in primiparous pregnant women, and the Descriptive Questionnaire and General Comfort Scale (GAS) will be applied.
BACKGROUND AND AIM: Inflammatory diseases often result in bone loss due to persistent inflammation, which activates osteoclasts and increases bone resorption. Oxysophocarpine (OSC), a bioalkaloid extracted from the roots of Sophora japonica and other leguminous plants, has neuroprotective and anti-tumor properties. However, it is still uncertain whether OSC can effectively inhibit the differentiation of osteoclasts and bone resorption. Therefore, this study explored the potential role of OSC in osteoclast formation and inflammatory osteolysis and its underlying mechanisms.
EXPERIMENTAL PROCEDURE: This study involved inducing primary mouse bone marrow macrophages (BMMs) into osteoclasts using macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL) and examined the effects of OSC on osteoclast (OC) differentiation, function, and intracellular reactive oxygen species (ROS) production. The impact of OSC on the expression of osteoclast-specific genes and inflammation-related factors was assessed using real-time quantitative PCR. Additionally, changes in oxidative stress-related factors, NF-κB, and MAPK signaling pathways were examined using western blotting. Finally, this study investigated the influence of OSC on a mouse cranial bone resorption model induced by titanium (Ti) particles in vivo.
RESULTS: OSC inhibited OC differentiation and resorption and reduces intracellular ROS levels. Moreover, OSC suppressed IL-1β, TNF-α, IL-6, and osteoclast-specific gene transcription while increasing Nrf2 and HO-1 protein expression. Furthermore, OSC inhibited the expression and autoregulation of the NFATc1 gene, ultimately leading to a reduction in Ti particle-induced bone resorption in mice.
CONCLUSION: OSC could be regarded as an innovative medication for the treatment of osteoclast-associated inflammatory osteolytic diseases.
A baseline venous sample of 5 ml of venous will be drawn for pre-infusion measurement. Under sterile conditions 0.5 mg/kg body weight of ICG will be injected into vein. Further blood samples (5 ml each) will be collected at 5, 10, 15 and 20 minute intervals after the injection from a peripheral vein in the opposite arm using another intravenous catheter. After serum is separated by centrifugation, optical densities will be measured at 804 nm using a calibrated method for measurement of ICG level s. ICG retention at 15 minutes and elimination rate constant will be calculated by fitting the serum disappearance curve to a single exponential decay equation.This will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
Female healthy controls, age 16-50 with normal to mild overweight (18.5 ≤ BMI\< 27 kg/m2). .
Fibroblast growth factor-2 (FGF-2) is acutely cardioprotective towards non-ischemic as well as ischemic myocardium. The potent mitogenic activity of FGF-2, however, may pose limitations to some of its clinical applications. In this study we examined whether a recombinant FGF-2 mutant (S117A) that is no longer mitogenic retains cardioprotective properties. Administration of S117A FGF-2 after 30 min of ischemia and during reperfusion of the ex vivo perfused rat heart resulted in significant protection (comparable to that of wild type FGF-2) against myocardial contractile dysfunction. In an in vivo study, rat myocardial infarction was induced by irreversible left coronary ligation; S117A FGF-2, or saline, were administered by direct intramyocardial injection into the ischemic left front ventricular wall. One day later: infarct size (assessed histologically), and plasma cTnT levels (assessed by Western blotting) were significantly decreased in the S117A FGF-2-, compared to the saline- treated control group, by 32.2% (P<0.01) or 28.5 % (P<0.01), respectively;systolic pressure, rates of contraction and relaxation and developed pressure, assessed in the Langendorff mode, were significantly increased in the S117A FGF-2 group compared to saline-treated group. One week after infarction, echocardiography showed significantly improved contractile function (ejection fraction, fractional shortening), in the S117A FGF-2 or wild type FGF-2 treated hearts compared to the saline treated group. At 6 weeks post infarction, however, S117 FGF-2-treated hearts had similar scar size and contractile function (systolic pressure, developed pressure, rates of contraction and relaxation, ejection fraction, fractional shortening) to the saline-treated group, while wild type FGF-2-treated hearts continued to display significantly improved contractility and reduced scar size. The wild type-, but not S117-, FGF-2-treated group had significantly increased microvessel density at or near the scar area. It is concluded that acute cardioprotection by FGF-2 against ischemia and/or reperfusion -induced contractile dysfunction and tissue damage is independent of its mitogenic/ angiogenic activity.   Thus the non-mitogenic, non-angiogenic S117 FGF-2 may serve as an agent of secondary injury prevention during early (one week) management of myocardial infarction and re-establishment of blood flow. Long-term protection of underperfused myocardium is likely to require increased vessel formation, and the mitogenic/angiogenic activity of wild type FGF-2.
A physician in an emergency room inputs a radiology order into a first mobile device. A radiologist receives the order over a second mobile device and inputs a report into the device. The devices provide prompts to input the information according to American College of Radiology guidelines. Information summaries for billing are produced. Physicians who frequently input inappropriate orders can be identified. A learning system uses patient clinical outcomes and pathology results to assess the usefulness of the examinations being performed.
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.
This will be a randomized controlled trail. After approval from ethical committee, data will be collected from rising sun institute of special education, Lahore. Total sample size will be 20 and there will be two groups. Group A will be given with Standard Physical therapy treatment twice a week for 8 weeks. While group B will be given with plyometric exercises along with standard physical therapy treatment twice a week for 8 weeks. Patients will be evaluated before and after the intervention on Pediatric balance scale, time up and go test, five times sit to stand. Data will be analyzed on SPSS 26.0 and necessary analysis will be done after checking the normality of data.
New product obtainable from collagen contains 25-50 pts. monomeric, 25-50 pts. polymeric and 0-40 pts. highly polymeric collagen. At advantageously additionally contains proline so that the total proline content is up to 40%. The product is suitable for the treatment of open wounds, since it strongly stimulates wound granulation. It is also suitable for cosmetic purposes, on account of its moisturizing and reparative action.
PURPOSE: A functional natural cosmetic composition containing purified bee venom and natural extract is provided to ensure anti-inflammation, antibacteria, and antioxidation. CONSTITUTION: A cosmetic composition for antioxidation and antibacterial contains extract of bee venom, Acer palmatum Var. amoenum extract, and Callicarpa japonica var. Thunb extract as an active ingredient. The extract is prepared by suspending Acer palmatum Var. amoenum or Callicarpa japonica var. Thunb using water, organic solvent, or mixture thereof, adding hexane, chloroform, ethyl acetate, and butanol in order to prepare a fraction; and a step of purifying ethyl acetate fraction.